EGFR and non-small cell lung carcinoma: A phase II single arm study presented afatinib in NSCLC with EGFR activating mutations [17] and the efficacy of afatinib was compared with chemotherapy or erlotinib in a series of phase III RCTs named LUX-Lung [18].